Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07816562

Ovulation Trigger Strategies in Low Ovarian Reserve (TRIGGERBEST)

This study aims to compare different ovulation triggering strategies in women with low ovarian reserve undergoing fresh in vitro fertilization (IVF) cycles.

Ovulation triggering is a key step in IVF treatment, as it determines final oocyte maturation prior to oocyte retrieval.

Participants are randomly assigned to one of three ovulation trigger approaches: human chorionic gonadotropin (hCG) alone, follitropin delta combined with hCG, or dual trigger using a gonadotropin-releasing hormone (GnRH) agonist plus hCG.

The primary objective is to evaluate wether adding follitropin delta at the time of triggering increases the number of matura oocytes obtained, without adversely affecting implantation rates. Pregnancy otucomes following fresh embryo transfer will also be assessed.

The results of this study may help optimize ovulation triggering strategies in women with low ovarian reserve undergoing IVF treatment.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–42 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

Hospital Clínico Universitario de Valencia

Valencia, 46010, Spain

Location status: Recruiting

Location contact

Cesar Lizan Tudela

CONTACT

[email protected]

+34 96 197 3500

About this study

Final oocyte maturation is a critical step in assisted reproductive techniques (ART) and is largely determined by the ovulation triggering strategy. In women with low ovarian reserve, achieving an adequate number of mature oocytes remains a major challenge, even when established trigger protocols are used.

Dual trigger strategies combining hCG and a GnRH agonist are widely used in this population, based on evidence suggesting improved oocyte maturation. However, despite this approach, oocyte yield and maturity often remain suboptimal. The addition of exogenous follicle-stimulating hormone (FSH) activity at the time of ovulation triggering has been proposed as a potential strategy to further optimize final oocyte maturation.

Follitropin delta has a distinct pharmacokinetic profile and provides individualized FSH exposure based on ovarian reserve markers. Its use in combination with hCG at the time of triggering may enhance oocyte maturation without compromising endometrial receptivity.

This prospective, randomized study compares three ovulation triggering strategies in women with low ovarian reserve undergoing fresh IVF cycles: hCG alone, follitropin delta combined with hCG, and dual triggering using a GnRH agonist plus hCG. Participants are randomly assigned to one of the three groups.

The primary outcome is the number of mature oocytes (metaphase II, MII) obtained at oocyte retrieval. Secondary outcomes include the proportion of mature oocytes, biochemical pregnancy rate per embryo transfer, and ongoing pregnancy rate following fresh embryo transfer.

The study aims to generate evidence to optimize ovulation triggering strategies in women with low ovarian reserve.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed informed consent.
  • Women aged between 18 and 42 years.
  • Primary infertility.
  • Women with low ovarian response classified within one of the groups defined by the POSEIDON criteria.

Exclusion criteria

  • More than two previous failed ovarian stimulation cycles.
  • Female age >42 years.
  • Body mass index (BMI) >35 kg/m².
  • Criteria of extremely low ovarian reserve according to the Spanish National Health System exclusion criteria (AMH <0.3 ng/mL and/or antral follicle count <5).
  • Male partner age >55 years.
  • Severe male factor infertility (total motile sperm count <1 million).
  • Previous voluntary sterilization (vasectomy or bilateral tubal ligation).
  • Previous healthy child shared by the couple.
  • Presence of medical conditions contraindicating pregnancy.
  • Risk of ovarian hyperstimulation syndrome (OHSS). If more than 15 follicles are expected on the day of trigger, the patient will be excluded from the study.

Treatment and study plan

human chorionic gonadotropin (hCG)

Drug

Human chorionic gonadotropin (hCG) administered for final oocyte maturation and ovulation triggering.

Other names: hCG

Follitropin delta

Drug

Follitropin delta administered as part of the ovulation-triggering regimen for final oocyte maturation.

(hCG).

Triptorelin

Drug

Triptorelin, a gonadotropin-releasing hormone (GnRH) agonist, administered as part of the ovulation-triggering regimen for final oocyte maturation.

Primary outcomes

  1. Number of mature oocytes (MII)

    Time frame: During the oocyte retrieval procedure

    Number of metaphase II (MII) oocytes obtained at oocyte retrieval following ovulation triggering

Secondary outcomes

  1. Proportion of mature oocytes

    Time frame: During the oocyte retrieval procedure

    Percentage of metaphase II (MII) oocytes relative to the total number of oocytes retrieved.

  2. Biochemical pregnancy rate per embryo transfer

    Time frame: 10-14 days after embryo transfer

    Positive beta-human chorionic gonadotropin (beta-hCG) test following fresh embryo transfer.

  3. Ongoing pregnancy rate

    Time frame: 6-7 weeks of gestation

    Presence of a viable intrauterine pregnancy confirmed by ultrasound.

Study contacts

Contact information is provided by the study sponsor or research team.

Cesar Lizan Tudela

CONTACT

[email protected]

+34 96 197 3500

Sponsors and collaborators

Lead sponsor

Fundación para la Investigación del Hospital Clínico de Valencia

Other

Collaborators

  • Ferring Pharmaceuticals
  • Hospital Clínico Universitario de Valencia

Registry information

Official study title

Ovulation Trigger Strategies in Women With Low Ovarian Reserve Undergoing Fresh In Vitro Fertilization Cycles: A Prospective Randomized Controlled Trial (TRIGGERBEST)

Acronym: TRIGGERBEST

Important dates

Study start
2024
Primary completion
2027
Study completion
2028
First posted
Sep 11, 2026
Registry last updated
Sep 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.